BGLAF (BioGaia AB) Interest Coverage : 10.76 (As of Dec. 2024)

View and export this data going back to 2013. Start your Free Trial

What is BioGaia AB Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. BioGaia AB's Operating Income for the three months ended in Dec. 2024 was $9.4 Mil. BioGaia AB's Interest Expense for the three months ended in Dec. 2024 was $-0.9 Mil. BioGaia AB's interest coverage for the quarter that ended in Dec. 2024 was 10.76. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for BioGaia AB's Interest Coverage or its related term are showing as below:

BGLAF' s Interest Coverage Range Over the Past 10 Years
Min: 28.04 Med: 357.2 Max: 1598.45
Current: 28.37

BGLAF's Interest Coverage is ranked better than
64.17% of 667 companies
in the Drug Manufacturers industry
Industry Median: 12.63 vs BGLAF: 28.37

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

BioGaia AB Interest Coverage Historical Data

The historical data trend for BioGaia AB's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

BioGaia AB Interest Coverage Chart

BioGaia AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Coverage

Get a 7-Day Free Trial

341.44

213.52

62.13

28.05

28.36

BioGaia AB Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Interest Coverage	Get a 7-Day Free Trial															6.10	92.93	91.55	18.08	10.76

Competitive Comparison of BioGaia AB's Interest Coverage

For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioGaia AB's Interest Coverage Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's Interest Coverage distribution charts can be found below:

* The bar in red indicates where BioGaia AB's Interest Coverage falls into.

Save Embed

;

Save Embed

;

BioGaia AB Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

BioGaia AB's Interest Coverage for the fiscal year that ended in Dec. 2024 is calculated as

Here, for the fiscal year that ended in Dec. 2024, BioGaia AB's Interest Expense was $-1.4 Mil. Its Operating Income was $38.5 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.0 Mil.

Interest Coverage	=	-1	*	Operating Income (A: Dec. 2024 )	/	Interest Expense (A: Dec. 2024 )
	=	-1	*	38.541	/	-1.359
	=	28.36

BioGaia AB's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

Here, for the three months ended in Dec. 2024, BioGaia AB's Interest Expense was $-0.9 Mil. Its Operating Income was $9.4 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.0 Mil.

Interest Coverage	=	-1	*	Operating Income (Q: Dec. 2024 )	/	Interest Expense (Q: Dec. 2024 )
	=	-1	*	9.412	/	-0.875
	=	10.76

The higher the ratio, the stronger the company's Financial Strength is.

BioGaia AB (OTCPK:BGLAF) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

BioGaia AB Interest Coverage Related Terms

Thank you for viewing the detailed overview of BioGaia AB's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

BioGaia AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioGaia AB (OTCPK:BGLAF) » Definitions » Interest Coverage

Traded in Other Exchanges

BIOGY:USA BIOG B:Sweden BIOGBs:UK 0GTN:UK BGLA:Germany

Address

Kungsbroplan 3A, Stockholm, SWE, SE-112 27

Website

https://www.biogaia.se

BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions; Asia Pacific, Europe, the Middle East, Africa, and the Americas.